Clinical trials in L'hospitalet De Llobregat – page 49

988 clinical trials in L'hospitalet De Llobregat, Spain across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in SpainEnsayosClinicos.es

L'hospitalet De Llobregat at a glance

988

clinical trials

Research sites4

Quick filters

988 trials in L'hospitalet De Llobregat

Open in trial search

Acute myeloid leukaemia+1

Not recruiting

Study Comparing Gilteritinib and Midostaurin with Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with FLT3 Mutation

Registered drugNo placebo

Study Comparing Gilteritinib and Midostaurin with Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with FLT3 Mutation

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Gilteritinib
Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Contact Research Centre

B-cell lymphoma recurrent+1

Not recruiting

Study on the Safety and Effectiveness of Glofitamab and Obinutuzumab for Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Registered drugNo placebo

Study on the Safety and Effectiveness of Glofitamab and Obinutuzumab for Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Glofitamab
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Diabetic retinopathy+1

Not recruiting

Study on the Effectiveness and Safety of BAY 3283142 in Reducing Urine Albumin for Patients with Chronic Kidney Disease

Investigational

Study on the Effectiveness and Safety of BAY 3283142 in Reducing Urine Albumin for Patients with Chronic Kidney Disease

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:BAY 3283142
Sponsor:Bayer AG

Contact Research Centre

Acute kidney injury

Not recruiting

Study on TIN816 for Preventing Acute Kidney Injury in Adults Undergoing Cardiac Surgery

Investigational

Study on TIN816 for Preventing Acute Kidney Injury in Adults Undergoing Cardiac Surgery

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:TIN816
Sponsor:Novartis Pharma AG

Contact Research Centre

Bladder cancer

Not recruiting

Study on Erdafitinib and Cetrelimab for Patients with Muscle-Invasive Bladder Cancer Ineligible for Cisplatin Treatment

InvestigationalNo placebo

Study on Erdafitinib and Cetrelimab for Patients with Muscle-Invasive Bladder Cancer Ineligible for Cisplatin Treatment

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Cetrelimab
Sponsor:Grupo Espanol De Oncologia Genitourinaria-Socug

Contact Research Centre

Neoplasm

Not recruiting

Study on NECVAX-NEO1 with PD-1/PD-L1 Inhibitors for Patients with Advanced Solid Tumors

InvestigationalNo placebo

Study on NECVAX-NEO1 with PD-1/PD-L1 Inhibitors for Patients with Advanced Solid Tumors

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Necvax-Neo1
Sponsor:NEC Bio Therapeutics GmbH

Contact Research Centre

Uveal melanoma

Not recruiting

Study of Darovasertib and Crizotinib for Patients with Metastatic Uveal Melanoma Who Are HLA-A2 Negative

Registered drugNo placebo

Study of Darovasertib and Crizotinib for Patients with Metastatic Uveal Melanoma Who Are HLA-A2 Negative

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Crizotinib
Sponsor:Ideaya Biosciences Inc.

Contact Research Centre

Study of BI-1206, Rituximab, and Acalabrutinib for Patients with Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphoma

Not recruiting

Registered drugNo placebo

Study of BI-1206, Rituximab, and Acalabrutinib for Patients with Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphoma

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Acalabrutinib
Sponsor:Bioinvent International AB

Contact Research Centre

Acute myeloid leukaemia

Not recruiting

Study of venetoclax and azacitidine combination treatment for acute myeloid leukemia patients with measurable residual disease after chemotherapy or before stem cell transplant

Registered drugNo placebo

Study of venetoclax and azacitidine combination treatment for acute myeloid leukemia patients with measurable residual disease after chemotherapy or before stem cell transplant

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Azacitidine
Sponsor:Grupo Cooperativo De Estudio Y Tratamiento De Las Leucemias Agudas Y Mielodisplasias

Contact Research Centre

Plasma cell myeloma

Not recruiting

Study of Talquetamab and Teclistamab for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo

Study of Talquetamab and Teclistamab for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Daratumumab
Sponsor:Janssen Cilag International

Contact Research Centre

Study on the Effects of FDY-5301 for Patients with Anterior ST-Elevation Myocardial Infarction (Heart Attack)

Not recruiting

Investigational

Study on the Effects of FDY-5301 for Patients with Anterior ST-Elevation Myocardial Infarction (Heart Attack)

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Sodium Iodide
Sponsor:Faraday Pharmaceuticals Inc.

Contact Research Centre

Acute myeloid leukaemia+10

Not recruiting

Long-Term Access to Ibrutinib for Patients with Lymphoma, Leukemia, and Other Conditions

InvestigationalNo placebo

Long-Term Access to Ibrutinib for Patients with Lymphoma, Leukemia, and Other Conditions

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Ibrutinib
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in L'hospitalet De Llobregat

What the registry says about research in the country

01 Infectious Disease Prevention

Innovative research focused on vaccine development targeting multiple infectious diseases, including studies on UTI prevention, yellow fever, and RSV protection in adults.

UTI Vaccine Safety & Efficacy
Yellow Fever Immunization
RSV Protection Studies

These trials aim to enhance vaccine effectiveness and improve public health outcomes through preventive measures.

02 Oncology Research

Comprehensive studies exploring new treatments for various types of advanced cancers, with particular focus on targeted therapies and novel drug combinations.

Colorectal Cancer Treatment
Gastric Cancer Therapies
Pancreatic Cancer Interventions

Advanced clinical research investigating innovative approaches to combat various forms of cancer.

03 Transplant Medicine

Groundbreaking research in kidney transplantation, focusing on preventing rejection and improving post-transplant outcomes.

Antibody-Mediated Rejection
Delayed Graft Function
Novel Immunosuppressive Approaches

Studies aimed at enhancing transplant success rates and patient recovery.

04 Autoimmune Conditions

Clinical investigations into treatments for various autoimmune disorders, including innovative therapies for inflammatory conditions.

Psoriatic Arthritis Treatment
Atopic Dermatitis Management
Myasthenia Gravis Therapy

Focused on developing targeted treatments to improve patient quality of life.

Back to Spain All countries